Understanding Childhood Leukemia and Nutrition
This observational study, called the InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort, aims to learn more about how nutrition affects children and adolescents with Acute Lymphoblastic Leukemia (ALL). Researchers will collect information and samples (like stool and blood) at different times during treatment and up to one year after treatment ends. This will help create a valuable resource for future studies on how cancer progresses, how patients respond to treatment, and any long-term effects. This study is not testing a new intervention; instead, it's gathering information to better understand the role of nutrition. You may be able to join if you are between 3 and 18 years old, have been recently diagnosed with B-cell or T-cell ALL (a type of blood cancer), and are receiving treatment at a participating hospital. The study plans to enroll about 4900 participants, but its current recruitment status is unclear.
- Study design
- This is an observational study, meaning no new interventions are being tested. It aims to enroll approximately 4900 participants.
- What's involved
- Participants will provide biological samples (stool, blood) and sociodemographic and dietary data at diagnosis, end of induction, beginning of maintenance, end of treatment, and one year after treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to one year after treatment ends.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
At a glance
Conditions
Where it's being run
8 sites across 6 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Create a prospective multinational biorepository of pediatric specimens (stool, blood) obtained at diagnosis, end of induction, beginning of maintenance, end of treatment, and 1-year after treatment among children/adolescents with ALL.7 years
- Collect sociodemographic data at sequential timepoints during treatment for ALL.7 years
- Collect dietary data at sequential timepoints during treatment for ALL.7 years
- Collect physical activity data at sequential timepoints during treatment for ALL.7 years
- Collect clinical information (disease characteristics, treatment-related toxicities, survival) at sequential timepoints during treatment for ALL to accompany the biorepository of blood and stool specimens.7 years
- Collect nutritional anthropometrics at sequential timepoints during treatment for ALL to accompany the biorepository of blood and stool specimens.7 years